The market for Janus kinase (JAK) inhibitors, an oral autoimmune disease treatment drug, has expanded 2.4 times over the past three years. In addition to Xeljanz, which was leading the market, new products such as Olumiant and Rinvoq were added, and each product actively expanded its indications. Competition between major products is also getting fiercer. Olumiant overtook Xeljanz to become the No. 1 in the market in its fourth year of release, and Rinvoq grew more than four times last year compared to the previous year, rapidly catching up with Olumiant·Rinvoq.

According to IQVIA, a pharmaceutical market research institute, on the 27th, the size of the domestic JAK inhibitor market last year was 40.6